Kenvue Inc. (NYSE:KVUE) Shares Bought by Fifth Third Bancorp

Fifth Third Bancorp raised its holdings in Kenvue Inc. (NYSE:KVUE) by 4.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 236,875 shares of the company’s stock after acquiring an additional 11,160 shares during the quarter. Fifth Third Bancorp’s holdings in Kenvue were worth $5,680,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its holdings in Kenvue by 3.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company’s stock valued at $5,249,665,000 after acquiring an additional 8,211,748 shares during the period. Vanguard Group Inc. lifted its holdings in Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock valued at $4,665,908,000 after acquiring an additional 1,636,741 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock worth $2,085,070,000 after buying an additional 10,682,003 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Kenvue by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock worth $980,989,000 after buying an additional 1,391,854 shares during the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after buying an additional 16,269,721 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 2.7%

Kenvue stock opened at $21.44 on Friday. The stock has a market cap of $41.14 billion, a PE ratio of 40.46, a P/E/G ratio of 2.62 and a beta of 0.98. The stock has a 50-day moving average price of $23.02 and a 200 day moving average price of $22.52. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $25.17. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. The firm had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The firm’s quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.28 EPS. Equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.82%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Analyst Ratings Changes

KVUE has been the subject of several research reports. Redburn Atlantic initiated coverage on Kenvue in a research note on Thursday, April 10th. They set a “neutral” rating and a $23.50 price target for the company. Evercore ISI initiated coverage on Kenvue in a research note on Monday, March 24th. They set an “in-line” rating and a $25.00 price target for the company. Piper Sandler lifted their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Barclays lifted their price target on Kenvue from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Monday, May 12th. Finally, UBS Group lifted their price target on Kenvue from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Friday, May 9th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.